CONDITIONS TREATeD / RHEUMATOID ARTHRITIS

Regenerate. Repair. Restore.

Stem Cells Therapy for Rheumatoid Arthritis and Autoimmune Disease

WHAT IS STEM CELL THERAPY?

HOW STEM CELL THERAPY WILL HELP?

WHAT SETS US APART?

WHY STEM CELLS TRANSPLANT INSTITUTE?

The Stem Cells Transplant Institute in Costa Rica, uses human mesenchymal stem cells (hUC-MCSCs) for the treatment of rheumatoid arthritis.        
Stem cell treatment has been found to be promising for various autoimmune diseases like rheumatoid arthritis, and it has shown to help improve the following RA symptoms:

  • Pain
  • Stiffness
  • Swelling, warmth and redness
  • Fatigue
  • Fever
  • Sweating
  • Loss of appetite
  • Weight loss

What do we know about rheumatoid arthritis?

Rheumatoid arthritis is a chronic autoimmune and inflammatory disease that primarily affects the joints. It causes the destruction of the articular cartilage, resulting in pain, stiffness, and inflammation of the synovial membrane (the healthy tissue membrane that surrounds the joints).
The immune system is supposed to protect healthy tissue from foreign invaders such as bacteria, viruses, and germs. Rheumatoid arthritis occurs when the immune system mistakenly attacks the synovium, resulting in inflammation and thickening of the synovium, eventually destroying the cartilage and bone within the joint.
As the tendons and ligaments holding the joint together get damaged, the joint is no longer supported. In approximately 40% of people diagnosed with rheumatoid arthritis, the inflammation can affect more than just the joints. This condition also affects non-joint structures such as the skin, eyes, kidneys, blood vessels, nerve tissue, bone marrow, the heart, and lungs.
Although the exact cause of the disease is unknown, researchers believe it is caused by a combination of genetic and environmental factors.
Rheumatoid arthritis increases the risk of developing other serious health problems, such as:

  • Cardiovascular disease
  • Infections
  • Lung disease
  • Lymphoma
  • Obesity
  • Osteoporosis

Despite advances in FDA approved treatments, the following issues continue to exist:

  • Up to 30% of patients fail to respond to current treatment options
  • Even with the resolution of inflammation, joint injury may persist
  • Joints that have already been damaged will not heal, but further damage may occur

What are researchers investigating? Can stem cell therapy improve the symptoms of RA?

Researchers are focusing on developing treatment options that would not only treat the symptoms associated with rheumatoid arthritis, but also repair and replace the damaged tissue while reducing inflammation and preventing future tissue damage. Stem cell therapy for rheumatoid arthritis has been found to be safe.4,5 In two clinical trials, 225 patients with rheumatoid arthritis were investigated for the efficacy of mesenchymal stem cells. Results showed patients treated with mesenchymal stem cells had better efficacy than those patients in the control arms. 4,6,7 Research is ongoing, but with the urgent need for more effective treatments for Rheumatoid arthritis, particularly for those patients with the more progressive forms of the disease, the Stem Cells Transplant Institute believes the potential of all types of cell therapies must be explored. As of March 20th, 2019, ClinicalTrials.gov (https://clinicaltrials.gov) showed 6 ongoing clinical trials to evaluate the safety and efficacy of umbilical cord mesenchymal stem cells for the treatment of rheumatoid arthritis.

What are the advantages of human umbilical cord mesenchymal stem cells?

  • Abundant supply containing up to 10 times more stem cells than bone marrow or adipose derived stem cells
  • hUC-MSC have immunosuppressors and immunomodulatory properties that allow their use in any individual without rejection- Human Leukocyte Antigen (HLA) matching is not necessary
  • Greater proliferation ability than adult autologous stem cells
    They regenerate at a very rapid rate
  • They are young and very adaptive
  • They have not been impacted by the aging process
  • They have not been affected by environmental toxins
  • Umbilical cord stem cells can be administered multiple times over the course of days
  • Eliminates the need to collect stem cells from the patient’s fat or hip bone reducing pain and recovery time

UMBILICAL CORD DONATIONS

How Are the Stem Cells Collected?

Our clinic focuses on obtaining healthy stem cells exclusively from umbilical cord blood donors. We collect the placenta once the baby is born, with the parent’s informed consent. Additionally, we follow strict ethical guidelines and collect stem cells from reliable and reputable sources.

INTRAVENUS ADMINISTRATION

How Are the Stem Cells Administered?

Our nursing staff administers the stem cells through an intravenous and intra-pulmonary route. For the most effective outcomes, intravenous administration is preferred.

About the Stem Cells Transplant Institute

Our clinic is located in Costa Rica, which is one of the most popular medical tourism destinations for stem cell therapy. At the Stem Cells Transplant Institute, we have a skilled team of doctors and medical professionals who collect and administer stem cells to treat autism and other conditions. Every patient receives the most cost-effective and top-notch care from our dedicated team.

Please fill this form

Scientific References:

  1. Fu et al. Stem cell transplantation therapy in Parkinson’s disease. SpringerPlus (2015) 4:597
  2. Joyce et al. Mesenchymal stem cell for the treatment of neurodegenerative disease. Regen Med. 2010, November, 5(6)933-946. Doi:10.2217/rme.10.72
  3. Helena Vilaça-Faria, António J. Salgado and Fábio G.
  4. Teixeira Mesenchymal Stem Cells-derived Exosomes: A New Possible Therapeutic Strategy for Parkinson’s disease. Cells2019, 8(2), 118; doi:3390/cells8020118
    Teixeira, F.G.; Carvalho, M.M.; Neves-Carvalho, A.; Panchalingam, K.M.; Behie, L.A.; Pinto, L.; Sousa, N.; Salgado, A.J. Secretome of mesenchymal progenitors from the umbilical cord acts as modulator of neural/glial proliferation and differentiation. Stem Cell Rev.2015, 11, 288–297. [Google Scholar] [CrossRef] [PubMed]
  5. Gao, F.; Chiu, S.M.; Motan, D.A.; Zhang, Z.; Chen, L.; Ji, H.L.; Tse, H.F.; Fu, Q.L.; Lian, Q. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis.2016, 7, e2062. [Google Scholar] [CrossRef] [PubMed]
  6. Joyce, N.; Annett, G.; Wirthlin, L.; Olson, S.; Bauer, G.; Nolta, J.A. Mesenchymal stem cells for the treatment of neurodegenerative disease.  Med.2010, 5, 933–946. [Google Scholar] [CrossRef] [PubMed]
  7. Fraga, J.S.; Silva, N.A.; Lourenco, A.S.; Goncalves, V.; Neves, N.M.; Reis, R.L.; Rodrigues, A.J.; Manadas, B.; Sousa, N.; Salgado, A.J. Unveiling the effects of the secretome of mesenchymal progenitors from the umbilical cord in different neuronal cell populations. Biochimie2013, 95, 2297–2303. [Google Scholar] [CrossRef] [PubMed]
  8. Ribeiro, C.A.; Fraga, J.S.; Graos, M.; Neves, N.M.; Reis, R.L.; Gimble, J.M.; Sousa, N.; Salgado, A.J. The secretome of stem cells isolated from the adipose tissue and Wharton jelly acts differently on central nervous system derived cell populations. Stem Cell Res. Ther.2012, 3, 18. [Google Scholar] [CrossRef]
  9. Ribeiro, C.A.; Salgado, A.J.; Fraga, J.S.; Silva, N.A.; Reis, R.L.; Sousa, N. The secretome of bone marrow mesenchymal stem cells-conditioned media varies with time and drives a distinct effect on mature neurons and glial cells (primary cultures).  Tissue Eng. Regen. Med.2011, 5, 668–672. [Google Scholar] [CrossRef]
  10. Salgado, A.J.; Fraga, J.S.; Mesquita, A.R.; Neves, N.M.; Reis, R.L.; Sousa, N. Role of human umbilical cord mesenchymal progenitors conditioned media in neuronal/glial cell densities, viability, and proliferation. Stem Cells Dev.2010, 19, 1067–1074. [Google Scholar] [CrossRef]
  11. Martins, L.F.; Costa, R.O.; Pedro, J.R.; Aguiar, P.; Serra, S.C.; Teixeira, F.G.; Sousa, N.; Salgado, A.J.; Almeida, R.D. Mesenchymal stem cells secretome-induced axonal outgrowth is mediated by BDNF.  Rep.2017, 7, 4153. [Google Scholar] [CrossRef]
  12. Serra, S.C.; Costa, J.C.; Assuncao-Silva, R.C.; Teixeira, F.G.; Silva, N.A.; Anjo, S.I.; Manadas, B.; Gimble, J.M.; Behie, L.A.; Salgado, A.J. Influence of passage number on the impact of the secretome of adipose tissue stem cells on neural survival, neurodifferentiation and axonal growth. Biochimie2018, 155, 119–128. [Google Scholar] [CrossRef]
  13. Assuncao-Silva, R.C.; Mendes-Pinheiro, B.; Patricio, P.; Behie, L.A.; Teixeira, F.G.; Pinto, L.; Salgado, A.J. Exploiting the impact of the secretome of MSCs isolated from different tissue sources on neuronal differentiation and axonal growth. Biochimie2018, 155, 83–91. [Google Scholar] [CrossRef] [PubMed]